Galectin Therapeutics’ President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020

NORCROSS, Ga., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin, the Company’s President and CEO, will present at the 3^rd Global NASH Congress 2020 at the London Heathrow Marriott on Tuesday, February 11, at 3:00 p.m. (15:00) local time.

In his presentation, titled “Clinical development of belapectin (GR-MD-02), a galectin-3 inhibitor, in treatment of NASH cirrhosis,” Dr. Shlevin will discuss how Galectin-3 inhibition has been shown to be central to the fibrotic process involved in the development of NASH-related cirrhosis, and how belapectin (GR-MD-02), the company’s galectin-3 inhibitor, has been demonstrated in a Phase 2b trial to decrease hepatic venous pressure gradient in compensated NASH cirrhotic patients without varices at baseline. Dr. Shlevin will also outline how the results of Galectin’s Phase 2 clinical trial have provided guidance for an adaptively designed Phase 3 trial. This Phase 3 trial is designed with interim analysis aimed at reaffirming the efficacy early on and includes various adaptations to sample size, dose and duration to maximize the likelihood of success of the overall study. Additionally, he will discuss aspects of the trial designed to enhance patient enrollment and retention over the two years duration of treatment.

In addition to the presentation, Dr. Shlevin will also chair the morning session of the Metabolic Syndrome, Diabetes and NAFLD Symposium on Monday, February 10, beginning at 11:40 a.m. local time.

The 3^rd Global NASH Congress 2020, featuring over 60 individual talks, panels, and roundtable discussions, was designed to facilitate collaboration between the multiple communities working on NASH, NAFLD, obesity, diabetes, and metabolic syndrome.

About Galectin Therapeutics
Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer.